相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。RNA toxicity in non-coding repeat expansion disorders
Bart Swinnen et al.
EMBO JOURNAL (2020)
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Bruce E. Sands et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
100 years of modelling ligand-receptor binding and response: A focus on GPCRs
David B. Finlay et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
Daniel P. Judge et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
Diane E. Frank et al.
NEUROLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2020)
Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2020)
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia
PadmaKumar Narayanan et al.
NUCLEIC ACID THERAPEUTICS (2020)
Phosphorothioate modified oligonucleotide-protein interactions
Stanley T. Crooke et al.
NUCLEIC ACIDS RESEARCH (2020)
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
Rohit Loomba et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents
Stanley T. Crooke et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug
Alexandre J. Debacker et al.
MOLECULAR THERAPY (2020)
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Timothy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet et al.
EUROPEAN HEART JOURNAL (2020)
Gapmer Antisense Oligonucleotides Targeting 5S Ribosomal RNA Can Reduce Mature 5S Ribosomal RNA by Two Mechanisms
Adam J. Pollak et al.
NUCLEIC ACID THERAPEUTICS (2020)
Antisense Inhibition of Prekallikrein to Control Hereditary Angioedema
Danny M. Cohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Some ASOs that bind in the coding region of mRNAs and induce RNase H1 cleavage can cause increases in the pre-mRNAs that may blunt total activity
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2020)
Antisense oligonucleotide targeting of mRNAs encoding ENaC subunits α, β, and γ improves cystic fibrosis-like disease in mice
Chenguang Zhao et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Entering the Modern Era of Gene Therapy
Xavier M. Anguela et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
RNA-Targeted Therapeutics (vol 27, pg 714, 2018)
Stanley T. Crooke et al.
CELL METABOLISM (2019)
Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
Erin S. Morgan et al.
DIABETES CARE (2019)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Safety evaluation of 2-deoxy-2-fluoro nucleotides in GalNAc-siRNA conjugates
Maja M. Janas et al.
NUCLEIC ACIDS RESEARCH (2019)
IONIS-PKKRx a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
Jason D. Ferrone et al.
NUCLEIC ACID THERAPEUTICS (2019)
N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
Veronica J. Alexander et al.
EUROPEAN HEART JOURNAL (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
Michael T. Migawa et al.
NUCLEIC ACIDS RESEARCH (2019)
Current Development of siRNA Bioconjugates: From Research to the Clinic
Ivan Chernikov et al.
FRONTIERS IN PHARMACOLOGY (2019)
Antisense Oligonucleotide Therapies for Neurodegenerative Diseases
C. Frank Bennett et al.
Annual Review of Neuroscience (2019)
Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
Lindsay N. Alfano et al.
MEDICINE (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
mRNA levels can be reduced by antisense oligonucleotides via no-go decay pathway
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2019)
Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
Shiyu Wang et al.
NUCLEIC ACID THERAPEUTICS (2019)
Phase 1 Investigation of a Ligand-Conjugated Antisense Oligonucleotide with Increased Potency for the Treatment of Transthyretin Amyloidosis
Nicholas J. Viney et al.
JOURNAL OF CARDIAC FAILURE (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
J. L. Witztum et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly
Ying Wang et al.
NUCLEIC ACID THERAPEUTICS (2019)
Kinetic and subcellular analysis of PS-ASO/protein interactions with P54nrb and RNase H1
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2019)
Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Xiangjun Tang et al.
FRONTIERS IN ONCOLOGY (2019)
Integrated Assessment of the Clinical Performance of GalNAc3-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2019)
Next-Generation Sequencing Technologies
W. Richard McCombie et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay
Hans J. Gaus et al.
NUCLEIC ACIDS RESEARCH (2019)
Eteplirsen Treatment Attenuates Respiratory Decline in Ambulatory and Non-Ambulatory Patients with Duchenne Muscular Dystrophy
Navid Khan et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2018)
Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes
Andres Digenio et al.
DIABETES CARE (2018)
Locked nucleic acid: modality, diversity, and drug discovery
Peter H. Hagedorn et al.
DRUG DISCOVERY TODAY (2018)
A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly
Peter J. Trainer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
Discovery and development of new antibacterial drugs: learning from experience?
Nicole Jackson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
M. D. Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Acute hepatotoxicity of 2′ fluoro-modified 5-10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
Shiyu Wang et al.
NUCLEIC ACIDS RESEARCH (2018)
The Effects of 2-O-Methoxyethyl Oligonucleotides on Renal Function in Humans
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2018)
COPII vesicles can affect the activity of antisense oligonucleotides by facilitating the release of oligonucleotides from endocytic pathways
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2018)
Membrane Destabilization Induced by Lipid Species Increases Activity of Phosphorothioate-Antisense Oligonucleotides
Shiyu Wang et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
The Discovery of Insulin: An Important Milestone in the History of Medicine
Ignazio Vecchio et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
C. Ammala et al.
SCIENCE ADVANCES (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring
Jeremy D. Gale et al.
PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN (2018)
Alicaforsen for the treatment of inflammatory bowel disease
Vipul Jairath et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy
Xingxing Wu et al.
HUMAN MOLECULAR GENETICS (2017)
Alicaforsen in the treatment of pouchitis
Thomas Greuter et al.
IMMUNOTHERAPY (2017)
RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions
A. Robert MacLeod et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Xue-Hai Liang et al.
MOLECULAR THERAPY (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The impact of base stacking on the conformations and electrostatics of single-stranded DNA
Alex Plumridge et al.
NUCLEIC ACIDS RESEARCH (2017)
Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes
Michael Tanowitz et al.
NUCLEIC ACIDS RESEARCH (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2017)
Nucleic acid binding proteins affect the subcellular distribution of phosphorothioate antisense oligonucleotides
Jeffrey K. Bailey et al.
NUCLEIC ACIDS RESEARCH (2017)
The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides
Suzanne Paz et al.
NUCLEIC ACID THERAPEUTICS (2017)
The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
Stanley T. Crooke et al.
NUCLEIC ACID THERAPEUTICS (2017)
Molecular Mechanisms of Antisense Oligonucleotides
Stanley T. Crooke
NUCLEIC ACID THERAPEUTICS (2017)
First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2),in subjects with open-angle glaucoma undergoing glaucoma filtration surgery
Norbert Pfeiffer et al.
PLOS ONE (2017)
Transcriptomic analysis of the role of RasGEF1B circular RNA in the TLR4/LPS pathway
Wei Lun Ng et al.
SCIENTIFIC REPORTS (2017)
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2016)
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts
Sebastien A. Burel et al.
NUCLEIC ACIDS RESEARCH (2016)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K. N. Chi et al.
ANNALS OF ONCOLOGY (2016)
A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
S. Chowdhury et al.
EUROPEAN JOURNAL OF CANCER (2016)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
Stanley T. Crooke et al.
MOLECULAR THERAPY (2016)
Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames
Xue-hai Liang et al.
NATURE BIOTECHNOLOGY (2016)
Viable RNaseH1 knockout mice show RNaseH1 is essential for R loop processing, mitochondrial and liver function
Walt F. Lima et al.
NUCLEIC ACIDS RESEARCH (2016)
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2016)
RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery
Walt F. Lima et al.
NUCLEIC ACIDS RESEARCH (2016)
Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
Colton M. Miller et al.
NUCLEIC ACIDS RESEARCH (2016)
Development of a Quantitative BRET Affinity Assay for Nucleic Acid-Protein Interactions
Timothy A. Vickers et al.
PLOS ONE (2016)
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
Nathalie M. Goemans et al.
PLOS ONE (2016)
Renal Effects of Antisense-Mediated Inhibition of SGLT2
Leonie van Meer et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells
Daniela Castanotto et al.
NUCLEIC ACIDS RESEARCH (2015)
Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2015)
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2015)
2′-Fluoro-modified phosphorothioate oligonucleotide can cause rapid degradation of P54nrb and PSF
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs
Hartmut Jahns et al.
NATURE COMMUNICATIONS (2015)
Substitution of tryptophan 89 with tyrosine switches the DNA binding mode of PC4
Jinguang Huang et al.
SCIENTIFIC REPORTS (2015)
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients
Meike H. van der Ree et al.
ANTIVIRAL RESEARCH (2014)
The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia
Mary P. McGowan et al.
CLINICAL LIPIDOLOGY (2014)
Local and systemic tolerability of a 2′O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey
Robert A. Fey et al.
INHALATION TOXICOLOGY (2014)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Thomas Voit et al.
LANCET NEUROLOGY (2014)
CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS
Volker Limmroth et al.
NEUROLOGY (2014)
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
W. Brad Wan et al.
NUCLEIC ACIDS RESEARCH (2014)
Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures
Wen Shen et al.
NUCLEIC ACIDS RESEARCH (2014)
TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Defining the Factors That Contribute to On-Target Specificity of Antisense Oligonucleotides
Walt F. Lima et al.
PLOS ONE (2014)
Antisense Oligonucleotides Capable of Promoting Specific Target mRNA Reduction via Competing RNase H1-Dependent and Independent Mechanisms
Timothy A. Vickers et al.
PLOS ONE (2014)
Targeting of Repeated Sequences Unique to a Gene Results in Significant Increases in Antisense Oligonucleotide Potency
Timothy A. Vickers et al.
PLOS ONE (2014)
Transfection of siRNAs can alter miRNA levels and trigger non-specific protein degradation in mammalian cells
Xue-hai Liang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2013)
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
D. Bianchini et al.
BRITISH JOURNAL OF CANCER (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
Lars Petter Jordheim et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Treatment of HCV Infection by Targeting MicroRNA
Harry L. A. Janssen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9
Ekambar R. Kandimalla et al.
NUCLEIC ACIDS RESEARCH (2013)
Gene Expression Regulation by Upstream Open Reading Frames and Human Disease
Cristina Barbosa et al.
PLOS GENETICS (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Single-Stranded RNAs Use RNAi to Potently and Allele-Selectively Inhibit Mutant Huntingtin Expression
Dongbo Yu et al.
CELL (2012)
Single-Stranded siRNAs Activate RNAi in Animals
Walt F. Lima et al.
CELL (2012)
The Nicotinic Acetylcholine Receptor: The Founding Father of the Pentameric Ligand-gated Ion Channel Superfamily
Jean-Pierre Changeux
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Aptamer-Mediated Delivery of Splice-Switching Oligonucleotides to the Nuclei of Cancer Cells
Jonathan W. Kotula et al.
NUCLEIC ACID THERAPEUTICS (2012)
Pharmacodynamics and Subchronic Toxicity in Mice and Monkeys of ISIS 388626, a Second-Generation Antisense Oligonucleotide That Targets Human Sodium Glucose Cotransporter
Thomas A. Zanardi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Unique Gene-Silencing and Structural Properties of 2 '-Fluoro-Modified siRNAs
Muthiah Manoharan et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Efficient and specific knockdown of small non-coding RNAs in mammalian cells and in mice
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2011)
U1 adaptors result in reduction of multiple pre-mRNA species principally by sequestering U1snRNP
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2011)
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
Hong Zhang et al.
BLOOD (2010)
An Upstream Open Reading Frame and the Context of the Two AUG Codons Affect the Abundance of Mitochondrial and Nuclear RNase H1
Yutaka Suzuki et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Discovery of Innovative Small Molecule Therapeutics
Magid Abou-Gharbia
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Off-target and a portion of target-specific siRNA mediated mRNA degradation is Ago2 'Slicer' independent and can be mediated by Ago1
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Oral delivery of antisense oligonucleotides in man
Lloyd G. Tillman et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Enhancement of SMN2 Exon 7 inclusion by antisense oligonucleotides targeting the exon
Yimin Hua et al.
PLOS BIOLOGY (2007)
Anti-inflammatory activity of inhaled IL-4 receptor-α antisense oligonucleotide in mice
James G. Karras et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2007)
The positional influence of the helical geometry of the heteroduplex substrate on human RNase H1 catalysis
Walt F. Lima et al.
MOLECULAR PHARMACOLOGY (2007)
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate
Walt F. Lima et al.
MOLECULAR PHARMACOLOGY (2007)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial
PB Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
A global transcription cofactor bound to juxtaposed strands of unwound DNA
S Werten et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Non-CpG-containing antisense 2′-methoxyethyl oligonucleotides activate a proinflammatory response independent of toll-like receptor 9 or myeloid differentiation factor 88
JJ Senn et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Receptive substances: John Newport Langley (1852-1925) and his path to a receptor theory of drug action
AH Maehle
MEDICAL HISTORY (2004)
An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis
P Miner et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2004)
Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis
WF Lima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Human RNase H1 uses one tryptophan and two lysines to position the enzyme at the 3′-DNA/5′-RNA terminus of the heteroduplex substrate
WF Lima et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
An oxazaphospholidine approach for the stereocontrolled synthesis of oligonucleoside phosphorothioates
N Oka et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2003)
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents - A comparative analysis
TA Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
The emergence of the drug receptor theory
AH Maehle et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Paraspeckles: A novel nuclear domain
AH Fox et al.
CURRENT BIOLOGY (2002)
Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2
MD Mailman et al.
GENETICS IN MEDICINE (2002)
Investigating the structure of human RNase H1 by site-directed mutagenesis
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Fully modified 2′ MOE oligonucleotides redirect polyadenylation
TA Vickers et al.
NUCLEIC ACIDS RESEARCH (2001)
Variations in mRNA content have no effect on the potency of antisense oligonucleotides
L Miraglia et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
Phosphorothioate oligodeoxynucleotides: What is their origin and what is unique about them?
F Eckstein
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2000)
分享论文
